Skip to content

Ardelyx ARDX Current ratio

Current ratio at other companies

Amgen logo
AmgenAMGN
1.3×+0.1×
Bausch Health Companies logo
Bausch Health CompaniesBHC
1.3×0.0×
AbbVie logo
AbbVieABBV
0.8×0.0×
XER
Xeris Biopharma Holdings, Inc.XERS
2.1×+0.4×
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
2.9×-0.2×
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
5.5×-0.4×

Other financials

Income statement

See full
Revenue$94.5M+27.5%
Gross profit$89.7M+45.1%
Operating income-$32.8M+9.8%
Net income-$37.6M+8.6%
EPS (diluted)-$0.15+11.8%

Balance sheet

See full
Cash & equivalents$31.2M+1.3%
Total debt$208.3M+34.3%
Total equity$148.6M+2.0%
Total assets$504.5M+23.0%

Cash flow

See full
Operating cash flow-$32.2M+16.2%
CapEx$69.0K-78.8%
Free cash flow-$32.3M+16.7%

Valuation

See full
Market cap$1.53B+25.5%
Enterprise value$1.71B+27.1%
P/S3.6×+0.2×

Profitability

See full
Gross margin92.5%+7.9pp
Operating margin-25.4%
Net margin-13.6%
FCF margin-40.9%

Returns & leverage

See full
Return on equity-39.5%
Debt / equity1.4×+0.3×

Where this comes from

Calculated from Ardelyx’s reported figures.

Based on the most recent quarter.

The official record: Ardelyx’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ardelyx's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ardelyx's current ratio?
Ardelyx (ARDX) reported current ratio of 3.5× in Q1 2026.
How has Ardelyx's current ratio changed year-over-year?
Ardelyx's current ratio decreased by 15.5% year-over-year, from 4.1× to 3.5×.
What is the long-term trend for Ardelyx's current ratio?
Over 5 years (2020 to 2025), Ardelyx's current ratio has grown at a -8.8% compound annual growth rate (CAGR), from 6.9× to 4.3×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.